• A cream, containing topical steroid clobetasol propionate, applied on the entire skin surface is as effective as oral steroids (prednisone), causes less severe unwanted or harmful effects, and may ...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that the U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the ...
Regeneron and Sanofi Announce FDA Approval of Dupixent for Treatment of Bullous Pemphigoid in Adults
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults with bullous pemphigoid (BP), a chronic and debilitating skin disease primarily affecting the elderly ...
More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...
Dupixent is the first and only targeted therapy to receive FDA approval for bullous pemphigoid. The FDA has approved Regeneron’s and Sanofi’s Dupixent (dupilumab) as the first and only targeted ...
Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease ...
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...
All products featured on Self are independently selected by Self editors. However, when you buy something through our retail links, Condé Nast may earn an affiliate commission. Studio Romantic/Adobe ...
Hypothyroidism related to immunotherapy in elderly adults: Analysis of a Colombian oncology cohort. Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback